
Upamostat
CAS No. 590368-25-5
Upamostat( WX-671 )
Catalog No. M24583 CAS No. 590368-25-5
Upamostat is an inhibitor of a serine protease and is a urokinase plasminogen activator (uPA) inhibitor.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 222 | In Stock |
![]() ![]() |
10MG | 357 | In Stock |
![]() ![]() |
25MG | 597 | In Stock |
![]() ![]() |
50MG | 851 | In Stock |
![]() ![]() |
100MG | 1152 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameUpamostat
-
NoteResearch use only, not for human use.
-
Brief DescriptionUpamostat is an inhibitor of a serine protease and is a urokinase plasminogen activator (uPA) inhibitor.
-
DescriptionUpamostat is an inhibitor of a serine protease and is a urokinase plasminogen activator (uPA) inhibitor.(In Vitro):Upamostat is the urokinase plasminogen activator (uPA) inhibitor. Upamostat is the oral pro-drug of the active metabolite WX-UK1, a novel uPA inhibitor. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, which plays a major role in tumor invasion and metastasis. Upamostat is the orally available amidoxime- (i.e. hydroxyamidine-) prodrug of the pharmacologically active form, WX-UK1.(In Vivo):The validated method is used to evaluate the pharmacokinetics of Upamostat (Mesupron) in rats. The mean plasma concentrations of Upamostat after a single intravenous injection of 2 mg/kg in five rats are measured. The substance decays in a mono-phasic pattern with a terminal half-life of 0.5 h; its volume of distribution is 2.0 L/kg, and clearance is about 2.7 L/h/kg.
-
In VitroUpamostat is the urokinase plasminogen activator (uPA) inhibitor. Upamostat is the oral pro-drug of the active metabolite WX-UK1, a novel uPA inhibitor. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, which plays a major role in tumor invasion and metastasis. Upamostat is the orally available amidoxime- (i.e. hydroxyamidine-) prodrug of the pharmacologically active form, WX-UK1.
-
In VivoThe validated method is used to evaluate the pharmacokinetics of Upamostat (Mesupron) in rats. The mean plasma concentrations of Upamostat after a single intravenous injection of 2 mg/kg in five rats are measured. The substance decays in a mono-phasic pattern with a terminal half-life of 0.5 h; its volume of distribution is 2.0 L/kg, and clearance is about 2.7 L/h/kg.
-
SynonymsWX-671
-
PathwayProteasome/Ubiquitin
-
TargetSerine Protease
-
RecptorSerine protease
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number590368-25-5
-
Formula Weight629.81
-
Molecular FormulaC32H47N5O6S
-
Purity>98% (HPLC)
-
SolubilityDMSO:250 mg/mL (396.95 mM)
-
SMILESCCOC(=O)N1CCN(CC1)C(=O)[C@H](CC2=CC(=CC=C2)/C(=N/O)/N)NS(=O)(=O)C3=C(C=C(C=C3C(C)C)C(C)C)C(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Heinemann V, et al. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
molnova catalog



related products
-
Isochlorogenic acid ...
Isochlorogenic acid C has antioxidant activity.
-
Upamostat
Upamostat is an inhibitor of a serine protease and is a urokinase plasminogen activator (uPA) inhibitor.
-
SLK/STK10-IN-1
SLK/STK10-IN-1 is a selective and potent inhibitor of SLK and STK10 with potential antitumor activity.